META-ANALYSIS OF THE ASSOCIATION BETWEEN A COMMON VARIANT IN THE BETA-2 ADRENERGIC RECEPTOR AND SUDDEN CARDIAC DEATH  by Gavin, Michael C. et al.
A130.E1214
JACC March 9, 2010
Volume 55, issue 10A
 QUALITY OF CARE AND OUTCOMES ASSESSMENT 
META-ANALYSIS OF THE ASSOCIATION BETWEEN A COMMON VARIANT IN THE BETA-2 ADRENERGIC 
RECEPTOR AND SUDDEN CARDIAC DEATH
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Sunday, March 14, 2010, 9:30 a.m.-10:30 a.m.
Session Title: Genetics and Cardiac Events
Abstract Category: Genetics and Clinical Outcomes
Presentation Number: 1027-155
Authors: Michael C. Gavin, Christopher Newton-Cheh, Martin Van Denbergh, J Michael Gaziano, Nancy R. Cook, Christine M. Albert, Brigham and 
Women’s Hospital, Boston, MA, Massachusetts General Hospital, Boston, MA
Background: Homozygosity of a common non-synonymous single nucleotide polymorphism (SNP) in the Beta-2 Adrenergic Receptor gene (ADRB2) 
that results in substitution of glutamine for glutamic acid at position 27 (Gln27Glu) has been inconsistently associated with an increased risk of 
sudden cardiac death (SCD). These discrepant results could be due to small sample sizes of individual studies, and no combined meta-analysis has 
been performed.
Methods and Results: We conducted a two part meta-analysis. First, to increase sample size, we determined genotypes for the Gln27Glu variant 
in 492 cases of sudden cardiac death and 1388 controls drawn from individuals of European ancestry enrolled in six prospective cohort studies. 
Cases were matched to controls on age, sex, cohort, history of CVD at the time of blood draw, and follow-up time. Conditional logistic regression 
with fixed effects meta-analysis assuming a recessive model, as previously reported in the literature, was used to test for association. When these six 
individual study results were combined in meta-analysis, homozygosity for the Gln27 allele conferred a non-significant increase in the age-adjusted 
odds ratio (OR) for SCD of 1.22 (95% CI: 0.98-1.53; P=0.08). After controlling for age, history of diabetes, hypertension, and high cholesterol, 
smoking status, body mass index, physical activity, aspirin use, alcohol intake, and parental history of early myocardial infarction, the association 
was statistically significant (OR=1.30, 95% CI: 1.01 to 1.67; P=0.046). When combined with two previous reports in an additional meta-analysis, 
there was a significant association between ADRB2 genotype and SCD (OR=1.31, 95% CI: 1.10-1.56; P=0.003).
Conclusions: Homozygosity for the Gln27 allele in ADRB2 is associated with a 30% increased risk of SCD in this combined meta-analysis of 730 
cases of SCD in population based studies.
